N-sec-butyl-4-aminopiperidine | 1016820-77-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-sec-butyl-4-aminopiperidine
• 英文别名: 1-(Sec-butyl)piperidin-4-amine；1-butan-2-ylpiperidin-4-amine
• CAS: 1016820-77-1
• 化学式: C₉H₂₀N₂
• 分子量: 156.271
• InChiKey: DBBKREWGWFNQHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-甲基水杨酸 、 N-sec-butyl-4-aminopiperidine 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-(1-butan-2-ylpiperidin-4-yl)-2-hydroxy-5-methylbenzamide
  参考文献：
  名称：

  Salicylamide inhibitors of influenza virus fusion

  摘要：

  Structural variation of the quinolizidine heterocycle of the influenza fusion inhibitor BMY-27709 was examined by several topological dissections in order to illuminate the critical features of the ring system. This exercise resulted in the identification of a series of synthetically more accessible decahydroquinolines that retained the structural elements of BMY-27709 important for antiviral activity. The 2-methyl-cis-decahydroquinoline 6f was the most potent influenza inhibitor identified that demonstrated an EC50 of 90 ng/mL in a plaque reduction assay. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00335-8
• 作为产物：
  描述：

  4-氨基哌啶 、 丁酮 在 sodium cyanoborohydride 作用下， 生成 N-sec-butyl-4-aminopiperidine
  参考文献：
  名称：

  Salicylamide inhibitors of influenza virus fusion

  摘要：

  Structural variation of the quinolizidine heterocycle of the influenza fusion inhibitor BMY-27709 was examined by several topological dissections in order to illuminate the critical features of the ring system. This exercise resulted in the identification of a series of synthetically more accessible decahydroquinolines that retained the structural elements of BMY-27709 important for antiviral activity. The 2-methyl-cis-decahydroquinoline 6f was the most potent influenza inhibitor identified that demonstrated an EC50 of 90 ng/mL in a plaque reduction assay. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00335-8

文献信息

• BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF
  申请人：Agency for Science, Technology, and Research

  公开号：US20190315755A1

  公开（公告）日：2019-10-17

  The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.
• US9580425B2
  申请人：——

  公开号：US9580425B2

  公开（公告）日：2017-02-28